A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With G… (NCT07441642) | Clinical Trial Compass
RecruitingPhase 2
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
United States, Australia, Bulgaria272 participantsStarted 2026-03-09
Plain-language summary
To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Who can participate
Age range
50 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Total GA area must be ≥2.5 and ≤17.5 mm2 (1 and 7 disk areas (DA), respectively)
. If GA lesion is multifocal, then the total lesion area must be between 2.5-17.5 mm2 and at least one lesion should have an area of at least 1.25 mm2
. Entire GA lesion must be visualized on the macula centered image and not contiguous with peripapillary atrophy
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This is a Phase 2 trial for FWY003 in geographic atrophy — what does that phase mean for what we currently know about whether this drug is safe and effective for my condition?
2Since the trial is measuring how much the geographic atrophy lesion area changes over time, how would my doctors track that in me, and how often would I need to come in for eye imaging or other tests?
3FWY003 is being compared against a placebo, which means I might not receive the active drug — given that, is there a standard-of-care treatment I should consider first, or would being on placebo put me at any disadvantage?
4Is this trial currently recruiting patients like me specifically — and what factors in my case, like the size or stage of my geographic atrophy, might affect whether this study would even be a realistic option to discuss with my retinal specialist?
5Are there any other ongoing or completed trials for geographic atrophy that my doctor thinks might be a better fit for my situation, so I can compare this option against what else is out there?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.